E Fund Management Co. Ltd. acquired a new position in shares of Ocugen, Inc. (NASDAQ:OCGN – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 48,412 shares of the company’s stock, valued at approximately $75,000.
Other institutional investors also recently modified their holdings of the company. David J Yvars Group purchased a new position in Ocugen in the 1st quarter worth approximately $35,000. Baader Bank Aktiengesellschaft purchased a new position in Ocugen in the second quarter worth $35,000. Victory Capital Management Inc. bought a new position in Ocugen in the second quarter valued at $51,000. Headlands Technologies LLC bought a new stake in Ocugen during the first quarter worth about $66,000. Finally, Daiwa Securities Group Inc. purchased a new position in shares of Ocugen in the 2nd quarter worth about $67,000. 10.27% of the stock is currently owned by institutional investors.
Ocugen Price Performance
Shares of Ocugen stock opened at $1.14 on Friday. The business’s 50-day moving average price is $1.36 and its 200-day moving average price is $1.45. The firm has a market capitalization of $293.38 million, a PE ratio of -4.56 and a beta of 3.69. Ocugen, Inc. has a 12 month low of $0.35 and a 12 month high of $2.11. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.09.
Ocugen Profile
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
See Also
- Five stocks we like better than Ocugen
- 3 Healthcare Dividend Stocks to Buy
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- The Significance of Brokerage Rankings in Stock Selection
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- When to Sell a Stock for Profit or Loss
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding OCGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocugen, Inc. (NASDAQ:OCGN – Free Report).
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.